You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,586,559


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,586,559
Title:Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Abstract: The present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for \"intronic splicing silencer\"), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).
Inventor(s): Singh; Ravindra N. (Shrewsbury, MA), Singh; Natalia N. (Shrewsbury, MA), Singh; Nirmal K. (Temple, TX), Androphy; Elliot J. (Natick, MA)
Assignee: University of Massachusetts (Boston, MA)
Application Number:13/329,926
Patent Claims:1. A method of increasing the level of exon 7-containing SMN2 mRNA in a cell, comprising contacting the cell with a peptide nucleic acid (PNA) that is at least 80% complementary to intron 7 of the SMN2 gene over the entire length of the PNA and is at least 85% complementary to the sequence set forth as SEQ ID NO:1 or SEQ ID NO:3, and wherein the PNA is 15-40 nucleobases in length, such that the level of exon 7-containing SMN2 mRNA in the cell is increased.

2. The method of claim 1, wherein the PNA is 10-15 nucleobases in length.

3. The method of claim 1, wherein PNA is 15-20 nucleobases in length.

4. The method of claim 1, wherein at least one nucleobase is a modified nucleobase.

5. The method of claim 1, wherein the method is performed in vitro.

6. The method of claim 5, wherein the cell is an embryonic stem cell.

7. A method of increasing the level of exon 7-containing SMN2 mRNA in an organism, comprising administering to the organism a peptide nucleic acid (PNA) that is at least 80% complementary to intron 7 of the SMN2 gene over the entire length of the PNA and is at least 85% complementary to the sequence set forth as SEQ ID NO:1 or SEQ ID NO:3, and wherein the PNA is 15-40 nucleobases in length, such that the level of exon 7-containing SMN2 mRNA in the organism extract is increased.

8. The method of claim 7, wherein the organism is a mammal.

9. The method of claim 7, wherein the organism is a human.

10. The method of claim 7, wherein the human has spinal muscular atrophy (SMA).

11. A method of treating spinal muscular atrophy (SMA) in a patient, comprising administering to the patient a peptide nucleic acid (PNA) that is at least 80% complementary to intron 7 of the SMN2 gene over the entire length of the PNA and is at least 85% complementary to the sequence set forth as SEQ ID NO:1 or SEQ ID NO:3, in a dose effective to increase the level of exon 7-containing SMN2 mRNA in cells of the patient, such that SMA in the patient is treated.

12. A method for inhibiting an SMN2 pre-mRNA intronic splicing silencer site in a cell comprising contacting the cell or cell extract with a peptide nucleic acid (PNA) 100% complementary to the ISSN-N1 sequence set forth in SEQ ID NO:1, such that the SMN2 intronic splicing silencer site is inhibited.

13. A method for inhibiting an SMN2 pre-mRNA intronic splicing silencer site in an organism comprising administering to the organism a peptide nucleic acid (PNA) 100% complementary to the ISSN-N1 sequence set forth in SEQ ID NO:1, such that the SMN2 intronic splicing silencer site is inhibited.

14. A method of administering a peptide nucleic acid to a subject that would benefit from enhanced levels of exon 7-containing SMN2 mRNA in neuronal cells, comprising administering to the subject a PNA that is at least 80% complementary to intron 7 of the SMN2 gene over the entire length of the PNA and is at least 85% complementary to the sequence set forth as SEQ ID NO:1 or SEQ ID NO:3, wherein the PNA is administered in a dose effective to enhance the level of exon 7-containing SMN2 mRNA in cells of the subject.

15. The method of claim 14, wherein the subject is suffering from amyotrophic lateral sclerosis (ALS).

16. The method of claim 1, wherein the method is performed in vivo.

17. The method of claim 5, wherein the cell is selected from the group consisting of a spinal muscular atrophy (SMA) patient-derived neuronal cell, a spinal muscular atrophy (SMA) patient-derived muscle cell and a spinal muscular atrophy (SMA) patient-derived fibroblast.

18. The method of claim 15, wherein the subject is suffering from spinal muscular atrophy (SMA).

19. The method of any one of claims 1, 7, 11 and 14, wherein the PNA is at least 90% complementary to the sequence set forth as SEQ ID NO:1 or SEQ ID NO:3.

20. The method of any one of claims 1, 7, 11 and 14, wherein the PNA is 100% complementary to the sequence set forth as SEQ ID NO:1 or SEQ ID NO:3.

21. The method of any one of claims 1, 7, 11 and 14, wherein the PNA is 100% complementary to intron 7 of the SMN2 gene over the entire length of the PNA.

22. The method of any one of claims 1, 7, 11 and 14, wherein the PNA is 20-25 nucleobases in length.

23. The method of any one of claims 1, 7, 11 and 14, wherein the PNA is 18 nucleobases in length.

24. The method of claim 4, wherein the nucleobase is derivitized at a position selected from the group consisting of the 5 position, the 7 position and the 8 position.

25. The method of claim 4, wherein the modified nucleobase is selected from the group consisting of 5-(2-amino)propyl uridine, 5-bromo uridine, 8-bromo guanosine, 7-deaza-adenosine, and N6-methyl adenosine.

26. The method of claim 1, which comprises the complement of the nucleobase sequence CCAGCAUUAUGAAAGUGAAU, set forth as nucleobases 10-29 of SEQ ID NO:103.

27. The method of claim 1, which consists of the complement of the nucleobase sequence CCAGCAUUAUGAAAGUGAAU, set forth as nucleobases 10-29 of SEQ ID NO:103.

Details for Patent 8,586,559

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2024-12-03
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2024-12-03
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2024-12-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.